CGChristian De Geyter

Christian De Geyter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian De Geyter has a total of 235 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single molecule footprinting measures low nucleosome occupancy in mature spermatozoa of mice and men

    by Laura Gaspa-Toneu, Haojun Shi, Evgeniy A. Ozonov, Mark. E. Gill, Christian De Geyter, Antoine H.F.M Peters

    Nucleosomes are fundamental units of DNA packaging and gene regulation in eukaryotes. In mammalian sperm, most nucleosomes are replaced by protamines causing extreme chromatin compaction. Various epigenomic studies reported conflicting results on the distribution of residual nucleosomes in mammalian sperm 1–9 , questioning their potential role in mediating intergenerational inheritance of paternal epigenetic information 10,11 . Here we performed single-molecule footprinting through Nucleosome Occupancy and Methylome (NOMe) sequencing 12 and applied the Bayesian statistical model nomeR 13 to determine frequencies of nucleosome removal and retention at 103 specific genomic regions in thousands of developing haploid spermatids and mature spermatozoa of mice. While we readily detected footprints of nucleosomes and the transcription factor CTCF in round spermatids, chromatin became transiently highly accessible in elongating spermatids with loss of such footprints, indicating extensive chromatin reprogramming during spermiogenesis. In mature sperm, following nuclear decondensation with recombinant nucleoplasmin, we measured nucleosome occupancy frequencies ranging ∼1.2 to 1.7% at mouse loci. In human sperm, nucleosome occupancy varied between ∼2.3 to 4.5% at 163 genomic loci profiled. Contrasting mice, chromatin in ∼25% of human sperm was accessible upon reducing disulfide bonds between protamines arguing for species specific protamine packaging. Our findings support a stochastic rather than programmed potential role of residual nucleosomes in mammalian sperm in regulating paternal gene expression during ensuing embryonic development.

  • Open Access

    Transdermal testosterone gel vs placebo in women with diminished ovarian reserve prior to in vitro fertilization: a randomized, clinical trial

    by Nikolaos P. Polyzos, Sebastian J. Leathersich, Francisca Martínez, Christophe Blockeel, Antonio Gosálvez, Laura de la Fuente, Anja Pinborg, Francesc Fàbregues, Dominic Stoop, Ignacio Rodriguez, et al.

    Diminished ovarian reserve (DOR) is common in women with infertility and is associated with poorer in vitro fertilization (IVF) outcomes. Testosterone is widely used off-label in this patient group, although evidence for its efficacy and safety is limited. To address this, we conducted a triple-blind, placebo-controlled, randomized clinical trial evaluating whether transdermal testosterone gel prior to IVF improves clinical pregnancy rates in women with DOR. Females aged 18-43 with infertility and DOR according to the Bologna criteria were recruited at 10 fertility clinics in Europe between April 2015 and November 2022. Of 316 assessed for eligibility, 290 were enrolled and randomized. Two were excluded from the primary analysis as their treatment coincided with the onset of the COVID-19 pandemic, and they did not start ovarian stimulation, leaving 288 participants. Participants were randomized to 5.5 mg of transdermal testosterone or matching placebo once daily for ~9 weeks prior to ovarian stimulation. All participants received ovarian stimulation in a long GnRH-agonist cycle with 300IU/day of highly purified human menopausal gonadotropin; fresh embryo transfer was performed if an embryo was available. The primary outcome was clinical pregnancy rate following fresh embryo transfer, defined as an intrauterine gestational sac with an embryo demonstrating cardiac activity at ≥7 weeks’ gestation. Of the 288 participants, 134 were randomized to testosterone and 154 to placebo. Clinical pregnancy rates did not differ significantly, occurring in 21 women (15.7%) in the testosterone group and 23 (14.9%) in the placebo group (risk ratio (RR), 1.05; 95% confidence interval (CI) 0.61 to 1.81, p = 0.86). The study was terminated for futility at the prespecified interim analysis based on a conditional power calculation once 70% of the target sample size were randomized. In this study, transdermal testosterone did not improve clinical pregnancy rates compared with placebo in patients with infertility and DOR. Trial Registration: ClinicalTrials.gov: NCT02418572, EudraCT: 2014-001835-35


  • Top Cited Papers

    ART in Europe, 2020: results generated from European registries by ESHRE

    by European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE), J Smeenk, C Wyns, Ch De Geyter, M S Kupka, C Bergh, I Cuevas Saiz, D De Neubourg, K Rezabek, A Tandler-Schneider, et al.

    STUDY QUESTION: What are the data and trends of ART and IUI cycle numbers and their outcomes, and of fertility preservation (FP) interventions, reported in 2020 as compared to previous years? SUMMARY ANSWER: This 24th ESHRE report highlights the number of ART treatment cycles and children born over the years, showing a decline in the total number of treatment cycles, when comparing 2020 with 2019, alongside a decline in twin deliveries owing to a decrease in transfers of multiple embryos; however, fresh IVF or ICSI cycles and frozen embryo transfers (FET) showed similar pregnancy rates, and the reported IUI cycle numbers decreased while maintaining stable outcomes. WHAT IS KNOWN ALREADY: ART aggregated data generated by national registries, clinics, or professional societies have been gathered and analyzed by the European IVF Monitoring (EIM) consortium since 1997 and reported in a total of 23 manuscripts published in Human Reproduction and Human Reproduction Open. STUDY DESIGN, SIZE, DURATION: Data on medically assisted reproduction (MAR) from European countries are collected by EIM for ESHRE each year. The data on treatment cycles performed between January 1 and December 31, 2020, were provided by either national registries or registries based on initiatives of medical associations and scientific organizations or committed persons in the 44 countries that are members of the EIM Consortium. PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 1440 clinics offering ART services in 41 countries reported 923 318 treatment cycles (−14%; in 2019: 1 077 813), including 135 231 with IVF, 356 408 with ICSI, 305 373 with FET, 57 051 with preimplantation genetic testing (PGT), 64 007 with oocyte donation, 353 with IVM of oocytes, and 4895 cycles using frozen oocytes. A total of 1288 institutions reported data on IUI cycles using either husband/partner’s semen (IUI-H; n = 112 663) or donor semen (IUI-D; n = 38 839) in 30 and 21 countries, respectively. Sixteen countries reported 29 566 interventions in pre-and post-pubertal patients for FP, including oocyte, ovarian tissue, semen, and testicular tissue banking. MAIN RESULTS AND THE ROLE OF CHANCE: In 24 countries (21 in 2019) in which all ART clinics reported to the registry, 356 427 treatment cycles were registered for a total population of approximately 268 million inhabitants in these countries, allowing the best estimate of a mean of 1330 cycles performed per million inhabitants (range: 142–3230). Among the reporting countries, for IVF, the clinical pregnancy rates (PR) per aspiration were similar to that in 2019 (22.1% versus 21.8% in 2019). For ICSI, the corresponding PRs showed similar trends (20.0% in 2020 versus 20.2% in 2019). When freeze-all cycles were excluded from the calculations, the clinical PRs per aspiration were 26.4% (28.5% in 2019) and 25.6% (26.2% in 2019) for IVF and ICSI, respectively. After oocyte donation, the PR per embryo transfer was 51.3% (50.5% in 2019) with freshly donated oocytes and 45.7% (44.8% in 2019) with thawed oocytes. After FET, the PR per thawing was 34.9% (versus 35.1% in 2019). In fresh cycles of both IVF and ICSI, the trend towards the transfer of fewer embryos continued with the transfer of 1, 2, 3, and ≥4 embryos in 57.2%, 37.8%, 4.8%, and 0.2%, of all treatments, respectively (corresponding to 55.4%, 39.9%, 2.6%, and 0.2% in 2019). This resulted in a reduced proportion of twin delivery rates (DRs) of 10.9% (11.9% in 2019) and a similar triplet DR of 0.2%. In FET cycles in 2020, the twin and triplet DRs were 7.9% and 0.1%, respectively (versus 8.9% and 0.1% in 2019). While the number of IUI cycles in 2020 decreased from 2019, the DRs remained stable at 8.8% after IUI-H (8.7% in 2019) and at 12.5% after IUI-D (12.1% in 2019). Twin and triplet DRs after IUI-H were 7.9% and 0.4% (in 2019: 8.7% and 0.4%) and 5.7% % and 0.1% after IUI-D (in 2019: 6.2% and 0.2%), respectively. Data on FP were provided by 16 countries (18 in 2019), reporting a total of 29 566 interventions (24 139 in 2019). Cryopreservation of ejaculated sperm (n = 21 864 versus n = 11 592 in 2019) and cryopreservation of oocytes (n = 6077 versus n = 10 784 in 2019) were the most frequently reported forms of FP. LIMITATIONS, REASONS FOR CAUTION: Caution with the interpretation of results should remain as data collection systems and completeness of reporting vary among European countries. Some countries were unable to deliver data about the number of initiated cycles and/or deliveries. WIDER IMPLICATIONS OF THE FINDINGS: The 24th ESHRE data collection on ART and IUI interventions shows a decrease of reported treatment cycles. A decline was observed when comparing 2020 with 2019, regarding the numbers of MAR treatments and births derived from these treatments in Europe. This break in the trend from prior years could be due to the effects of the COVID pandemic and/or due to the fact that some countries were not able to report. Although it is the largest data collection on MAR in Europe, further efforts to optimize both the collection and the reporting of data, from the perspective of improving surveillance and vigilance in the field of reproductive medicine, are awaited. STUDY FUNDING/COMPETING INTEREST(S): The study has received no external funding and all costs are covered by ESHRE. There are no competing interests.


  • Open Access

    “Age independent, but person dependent”: a Swiss interview-based study on the meaning of good parenthood at an advanced parental age

    by Nathalie Bettina Neeser, Andrea Martani, Veerle Provoost, Guido Pennings, Bernice Simone Elger, Christian De Geyter, Nicolas Vulliemoz, Tenzin Wangmo

    Background: Child welfare is one of the most important topics when it comes to parenting competence and the definition of good parenthood. This is widely discussed, especially in the context of treatment considerations for medically assisted reproduction (MAR) for patients of Advanced Parental Age (APA, here defined as 40 years and older). The aim of this study is to contribute to the exploration of how different stakeholders in this context envision the concept of good parenthood. Methods: An explorative semi-structured interview study was conducted with a total of 15 healthcare providers, 12 aspiring APA-parents, 21 APA-parents and 20 adult offspring of APA-parents. Results: After thematic analysis, results show that although the connecting focal point among participant groups is reproductive age, participants consistently emphasized that APA is not a determining factor to define a “good” parent. Instead, we identified three themes representing participants’ views on this topic: (i) the difficulties in defining good parenthood; (ii) the family structure and context as inherent to parenting quality; and (iii) good parents as conscious adapters. Conclusions: Participants expressed their views that good parenthood depends on the personality of the parent, rather than on one single characteristic of a parent, such as age. Our results challenge the focus on a singular parental characteristic in safeguarding the welfare of future children and therefore also the role currently attributed to parental age in decisions about access to MAR.

  • Open Access

    “It is our everyday life”. A Swiss interview-based study on care professionals’ experiences in assisting older patients to conceive with medically assisted reproduction

    by Andrea Martani, Nathalie Bettina Neeser, Kato Verghote, Christian de Geyter, Tenzin Wangmo

    Background: Medically assisted reproduction (MAR) has expanded the chances people have to reproduce, but it has also raised a number of ethical issues on how to use these technologies. One of the most relevant doubts concerns the possibility of granting access to MAR to older aspiring parents, considering that an increasing number of people have children at an advance parental age (APA). This generates not only abstract theoretical questions, but also concrete challenges and moral doubts for care professionals in their daily work. Methods: To investigate these issues, we conducted a qualitative exploratory study. After developing a semi-structured interview guide, we recruited and interviewed 15 care professionals in Switzerland working with older patients trying to conceive with MAR. Results: Through applied thematic analysis and collaborative auditing, we identified relevant themes in our data. First, our participants emphasised that they often work with older patients, who are part of the everyday work for MAR professionals. We then showed that professionals perceive older patients as particularly ‘on edge’ and thus have to adjust their work accordingly. Third we investigated the specificities that interacting with older patients during MAR treatment entail, including the need to be realistic about chances but also empathetic about emotional investment. Finally, we identified the struggles of professionals in assessing their patients as potential future parents. Conclusions: Our results show that professionals often perceive older patients as unaware of their advanced reproductive age, thus raising the question whether public health campaigns should better convey this message. It is also important to reflect on the struggles that professionals face in breaking bad news and balancing the desire to help older patients without fuelling false hopes. This shows the need of more widespread discussion and guidance on how to best provide care to this growing group of patients.


  • Open Access

    Normozoospermic infertile men possess subpopulations of sperm varying in DNA accessibility, relating to differing reproductive outcomes

    by Mark E Gill, Manuel Fischer, Christian De Geyter, Antoine H F M Peters

    STUDY QUESTION: Can a reliable assay be developed to quantify DNA accessibility in human sperm to help with the assessment of pre-implantation development affected by dense packaging of mammalian sperm’s genetic material? SUMMARY ANSWER: We adapted NicE-view, an assay that directly labels accessible DNA, for use in human sperm and applied it to examine spermatozoa from infertile individuals with distinct reproductive outcomes. WHAT IS KNOWN ALREADY: Existing data suggest a connection between sperm chromatin compaction and reproductive outcomes. The assays used to generate this data, however, measure chromatin compaction indirectly and thus understanding their meaning is challenging. STUDY DESIGN, SIZE, DURATION: Between April 2020 to December 2023, 60 normozoospermic infertile men were invited to participate in an experimental study and asked to provide a semen sample. PARTICIPANTS/MATERIALS, SETTING, METHODS: Among the 60 individuals forty had undergone at least one treatment with ART. Among these ART-treated participants, 20 were included in the study because after fertilization only one or no embryos developed during embryo culture (low blastocyst growth rate, LBGR). The other 20 men were included as at least 50% of cultured embryos developed to the blastocyst stage (high blastocyst growth rate). Additionally, 20 previously infertile individuals obtained a pregnancy naturally (NATP) and were included as well. Washed spermatozoa obtained from seminal plasma or prepared by swim-up procedure were processed for NicE-view to determine DNA accessibility as a marker of chromatin condensation using confocal microscopy. Images of more than 3 million spermatozoa were acquired. Computer-assisted image segmentation was used to identify individual sperm heads and DNA accessibility levels were then quantified in each. We also compared NicE-view to chromomycin A3 (CMA3), a conventional marker of chromatin de-condensation, and ATAC-see, an alternative assay for measuring DNA accessibility. MAIN RESULTS AND THE ROLE OF CHANCE: Both semen and swim-up samples of participants contained two well-delineated subpopulations of spermatozoa with distinct DNA accessibility levels, the frequencies of which varied among individuals. Interestingly, individuals with high frequencies of highly accessible sperm DNA, as measured in semen, possessed decreased sperm concentrations. Moreover, participants with high frequency of highly accessible sperm DNA were more common in the LBGR sub-group. Surprisingly, selection of motile sperm by swim-up enriched for sperm with high DNA accessibility in participants from all three sub-groups. Chromatin accessibility measurements by Nice-view were distinct from DNA staining with the fluorescent CMA3 dye, and NicE-view allowed much clearer separation of sperm subpopulations than ATAC-see. LIMITATIONS, REASONS FOR CAUTION: This was a single-centre study with a cohort of 60 individuals. Sperm samples containing very high frequencies of sperm with increased DNA accessibility were more common in the LBGR sub-group. The number of individuals with this pattern was, however, limited, even within this category. WIDER IMPLICATIONS OF THE FINDINGS: High DNA accessibility is associated with poor pre-implantation embryonic development in vitro and NicE-view may be used for the prediction of abnormal embryonic development in ART. Further studies examining samples from larger cohorts of participants and the localization of accessible regions within the sperm genome are needed to fully evaluate the utility of this method. STUDY FUNDING/COMPETING INTEREST(S): Swiss National Science Foundation (Grant No. 189264), Swiss Center for Applied Human Toxicology (SCAHT) research (Grant No. 1 ‘male reproductive toxicity’) (both to C.D.G.), and the Novartis Research Foundation (to A.H.F.M.P.). M.E.G., C.D.G., and A.H.F.M.P. are authors on a patent application (EP23210754.0) on the use of NicE-view for the assessment of sperm. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov ID NCT04256668.


  • Open Access

    A core outcome set for future male infertility research: development of an international consensus

    by Michael P. Rimmer, Ruth A. Howie, Richard A. Anderson, Christopher L.R. Barratt, Kurt T. Barnhart, Yusuf Beebeejaun, Ricardo Pimenta Bertolla, Pietro Bortoletto, Robert E. Brannigan, Astrid E.P. Cantineau, et al.


  • Open Access

    A core outcome set for future male infertility research: development of an international consensus

    by Michael P Rimmer, Ruth A Howie, Richard A Anderson, Christopher L R Barratt, Kurt T Barnhart, Yusuf Beebeejaun, Ricardo Pimenta Bertolla, Pietro Bortoletto, Robert E Brannigan, Astrid E P Cantineau, et al.

    STUDY QUESTION: Can a core outcome set be developed through a global consensus to standardize outcome selection, collection, comparison, and reporting in future male infertility trials? SUMMARY ANSWER: A minimum dataset, known as a ‘core outcome set’, has been developed for randomized controlled trials (RCTs) and systematic reviews evaluating potential interventions for male infertility. WHAT IS KNOWN ALREADY: Numerous factors, including a failure to consider the perspectives of men with lived experiences of infertility or their partners when developing and conducting RCTs can limit their clinical utility. Selection of outcomes, variations in outcome definitions, and the selective reporting of outcomes based on statistical analysis make the results of infertility research challenging to interpret, compare, and implement. For male infertility, this is further compounded by there being potentially three participants, the male, their female partner, and any offspring born, all with outcomes to be reported. This has led to significant heterogeneity in trial design and reporting. While a core outcome set for general infertility trials has been developed, there is no such outcome set for male infertility trials. STUDY DESIGN, SIZE, DURATION: A two-round Delphi survey (334 participants from 39 countries) and consensus development workshops (44 participants from 21 countries). PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, researchers, and men and women with infertility were brought together in a transparent process using formal consensus science methods. MAIN RESULTS AND THE ROLE OF CHANCE: The core outcome set for male infertility trials has been developed by the inclusion of specific male-factor outcomes in addition to the general infertility core outcome set. These outcomes include assessment of semen using the World Health Organization recommendations for semen analysis; viable intrauterine pregnancy confirmed by ultrasound (accounting for singleton, twin, and higher multiple pregnancies); pregnancy loss (accounting for ectopic pregnancy, miscarriage, stillbirth, and termination of pregnancy); live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital anomaly. Although not a requirement as part of the core outcome set, other outcomes were identified as potentially useful in certain study settings. LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods in this work, which have inherent limitations, including the representativeness of the participant sample, Delphi survey attrition, and an arbitrary consensus threshold. WIDER IMPLICATIONS OF THE FINDINGS: Embedding the core outcome set within RCTs and systematic reviews should ensure the comprehensive selection, collection, and reporting of core outcomes, which are inconsistently reported at present. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, and over 80 specialty journals, including the Cochrane Gynaecology and Fertility Group, Fertility and Sterility and Human Reproduction, have committed to implementing this core outcome set for male infertility trials. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by The Urology Foundation, Small Project Fund awarded to Michael P Rimmer at the University of Edinburgh, UK. RTM was supported by a United Kingdom Research and Innovation (UKRI) Future Leaders Fellowship (MR/Y011783/1). C.L.R.B. is the co-editor in chief of Human Reproduction and recipient of a BMGF grant and received consultancy fees from Exscentia and Exceed sperm testing, paid to the University of Dundee and speaking fees or honoraria paid personally by Ferring, Copper Surgical and RBMO. R.P.B. receives royalties from Flow diagnósticos. M.L.E. is an advisor to the companies Hannah, Illumicell, Next, Legacy, Doveras, Vseat and received a consultancy fee for this. B.W.M. is a paid consultant for Norgine and Organon and has received research funding from Ferring and Merck, he also receives consultancy and travel support from Merck. R.R.H. received royalties from Elsevier for a book, consultancy fees from Glyciome, and presentation fees from GryNumber Health and Aytu Bioscience. Attendance at Fertility 2020 and Roadshow South Africa by Ralf Henkel was funded by LogixX Pharma Ltd. R.R.H. is also Editor in Chief of Andrologia and has been an employee of LogixX Pharma Ltd. since 2020. M.S.K. has been an associate editor with Human Reproduction Open. K.Mc.E. received funding to attend Fertility 2025 by the British Fertility Society and is the Chair of the British Fertility Society. He is a member of the HFEA’s Scientific and Clinical Advances Advisory Committee and a Committee Member of the NICE Fertility Problems Guideline Group. M.H.V.L. receives consultation fees for the WHO Manual Spanish translation, and travel expenses for the ESHRE MRHI meeting in Budapest. She is a member of the editorial board for Fertility & Sterility, F&S Science, Human Reproduction, and Frontiers in Endocrinology. She is also a panel member of the World Health Organization (WHO) Human Reproduction Programme (HRP) Research Project Review Panel. R.S.M. is a member of the NICE Guideline Committee on Fertility and former chair of the British Fertility Society. A. Perheentupa receives an honoraria for lecturing from Merck for the Tackling Infertility manifest, Gedeon Richter & Ferring. A. Perheentupa declares lecture honoraria from Merck, Gideon Richter, and Ferring; and payment from Merck for the Tackling Infertility manifesto. A. Pacey receives consultancy fees for Carrot Fertility and Cryos International as well as lecturing for IBSA Institut Biochimique SA and Mealis Group—all fees paid to The University of Manchester. He is also a Trustee of Progress Educational. Trust (Charity Number 1139856) and Chairman of UKNEQAS Reproductive Sciences Advisory Committee. F.T. is the recipient...


  • Open Access

    EuMAR stakeholder engagement: an analysis of medically assisted reproduction (MAR) data collection practices in EU countries

    by Elena Achótegui Sebastián, Carlos Calhaz-Jorge, Christian De Geyter, Thomas Ebner, Carlos E Plancha, Veerle Goossens, Anja Pinborg, Nikolaos P Polyzos, Laura Rossignoli, Ioana Adina Rugescu, et al.

    STUDY QUESTION: What are the current national medically assisted reproduction (MAR) data collection systems across EU Member States, and how can these countries contribute to a unique, cycle-by-cycle registry for the European Monitoring of Medically Assisted Reproduction (EuMAR) project? SUMMARY ANSWER: The study identified significant variation in MAR data collection practices across Member States, with differences in data types, collection methods, and reporting requirements; the EuMAR project emerges as an opportunity to enhance data standardization and improve MAR data collection in the EU. WHAT IS KNOWN ALREADY: There is a need for new approaches in MAR data collection that include long-term and cross border follow-up. The EuMAR project intends to establish a unified, cycle-by-cycle registry of data on MAR treatments in EU countries, from which accurate cumulative outcomes can be calculated. STUDY DESIGN, SIZE, DURATION: This cross-sectional study involved a survey and interviews with stakeholders from 26 EU Member States conducted in 2023 over a period of seven months. PARTICIPANTS/MATERIALS, SETTING, METHODS: Representatives from national competent authorities and professional associations involved in MAR data collection in EU countries were invited to complete the survey and interviewed to assess current data flows, information requirements, and their interest in the EuMAR project. MAIN RESULTS AND THE ROLE OF CHANCE: Half of the participating countries reported having a national MAR registry with cycle-by-cycle data (n = 13), while 31% reported having a national registry with aggregated data (n = 8) and 19% reported having no national registry (n = 5). Of the countries with a national cycle-by-cycle registry, eight countries collect identifiable data, five countries collect pseudonymized data, and one country collects fully anonymized data. Informed consent is required in 10 countries. The main advantages that participants expected from a European registry like EuMAR were the possibility of obtaining national statistics in the absence of a national registry and improving the calculation of cumulative outcomes. LIMITATIONS, REASONS FOR CAUTION: The results of the study are based on self-reported data, which may be subject to bias, however, the validity of the collected information was verified with different means, including follow-up calls for clarifications and sharing final transcript reports. The feasibility of the proposed data flow models will be tested in a pilot study. WIDER IMPLICATIONS OF THE FINDINGS: Despite the heterogeneity of data collection practices across EU countries, the results show that stakeholders have high expectations of the benefits that the EuMAR registry can bring, namely the improvement of data consistency, cross-border comparability, and cumulative live birth rates, leading to better information for patients, health care providers and policy makers. STUDY FUNDING/COMPETING INTEREST(S): The EuMAR project was co-founded by ESHRE and the European Commission (101079865—EuMAR–EU4H-2021-PJ2). No competing interests were declared. TRIAL REGISTRATION NUMBER: N/A.